




Minimal-sedated Criteria



Sedated Criteria

Non-sedated Criteria

Patients who are developmentally and emotionally mature enough to cooperate with echocardiogram. Have demonstrated cooperation during previous interactions with medical personnel. Should be capable of lying still and cooperating for 30 minutes.







DELL CHILDREN'S MEDICAL CENTER EVIDENCE-BASED OUTCOMES CENTER



Addendum 1:

Principal Clinical Findings for Kawasaki Disease

- Bilateral conjunctival congestion

- Changes in lips and oral cavity: reddening of lips, strawberry tongue, diffuse injection of oral pharyngeal mucosa

- Polymorphous exanthema

- Changes in peripheral extremities: reddening of palms and soles, indurative edema (initial stage), membranous desquamation from fingertips (convalescent stage)

- Acute non-purulent cervical lymphadenopathy

Other clinical and laboratory findings:			
Cardiovascular:	Gastrointestinal:		
Congestive heart failure, myocarditis, pericarditis, valvular regurgitation	Diarrhea, vomiting, abdominal pain		
Coronary artery abnormalities	Hepatic dysfunction		
Aneurysms of medium-size noncoronary arteries	Hydrops of gallbladder		
Raynaud's phenomenon			
Peripheral gangrene			
Musculoskeletal system:	Genitourinary system:		
Arthritis, arthralgia	Uretrhitis/meatitis		
Central Nervous System:	Other findings:		
Irritability	Anterior uveitis (mild)		
Aseptic Meningitis	Desquamating rash in groin		
Sensorineural hearing loss			



DELL CHILDREN'S MEDICAL CENTER EVIDENCE-BASED OUTCOMES CENTER



Differential Diagnosis for Kawasaki Disease:	
Viral infections (adenovirus, EBV, enterovirus, measles infection)	
Flavivirus infections (Dengue, West Nile Virus, and Yellow Fever)	
Scarlet fever	
Staphylococcal scalded skin syndrome	
Toxic shock syndrome	
Acute rheumatic fever	
Bacterial cervical lymphadenitis	
Drug hypersensitivity reactions	
Stevens-Johnson Syndrome	
Juvenile idiopathic arthritis	
Rocky Mountain Spotted Fever	
Murine Typhus	
Acute Gastroenteritis (AGE) due to Yersinia	
Leptospirosis	
Mercury hypersensitivity reaction	

Medication

Medication	Dosing
<u>Aspirin</u>	See full table (KD Aspirin Dosing Table)
IVIG	2 g/kg/dose
Methylprednisolone	1 mg/kg/dose Q12hr (max 60 mg/day) For pulse dosing: 30 mg/kg/dose Q24 hr (max 1 g) for 3 days
Prednisolone	1 mg/kg/dose BID (max 60 mg/day)
Infliximab*	10 mg/kg/dose (*Consult Rheumatology)
Famotidine	0.5 mg/kg/dose BID (or per pharmacy protocol)





KD Aspirin Dosing Table

Weight Range			Tatal Daily Data
Low kg	High kg	Dose	Total Daily Dose (mg)
++++'	2.9	Individualized Weight Based Dosing	
3 _(54 mg/kg)	5.9 _(27.4 mg/kg)	40.5 mg (0.5 tab) Q6H	162
6 _(54 mg/kg)	9.9 _(32.7 mg/kg)	81 mg (1 tab) Q6H	324
10 _(48.6 mg/kg)	12.9 _(37.7 mg/kg)	121.5 mg (1.5 tabs) Q6H	486
13 _(49.8 mg/kg)	19.9 _(32.5 mg/kg)	162 mg (2 tabs) Q6H	648
20 _(48.6 mg/kg)	29.9 _(32.5 mg/kg)	243 mg (3 tabs) Q6H	972
30 _(43.2 mg/kg)	39.9 _(32.5 mg/kg)	324 mg (4 tabs) Q6H	1296
40 _(40.5 mg/kg)	49.9 _(32.5 mg/kg)	405 mg (5 tabs) Q6H	1620
50	++++'	Individualized Weight Based Dosing	
	Maintenance (Step-Dow	n) Dosing Recommendations Low Dose 3-5 m	ng/kg/day
Weight Range			Total Daily Dose
Low kg	High kg	Dose	(mg)
++++'	2.9	Individualized Weight Based Dosing	
4 (10 mg/kg)	13.9 _(3 mg/kg)	40.5 mg (0.5 tab) Qday	40.5
14 (5.8 mg/kg)	++++'	81 mg (1 tab) Qday	81

• Aspirin 81 mg tablets may be crushed/chewed and mixed with flavoring for immediate single dose administration. Aspirin 81 mg tablets CANNOT be compounded into a suspension for multi-dose administration.

• Aspirin 325 mg tablets are enteric coated (EC) and CANNOT be crushed or chewed.

• Substitution with 325 mg tablets may be considered for patients on high doses and patients able to tolerate swallowing tablets whole.

• Maximum daily dose = 4000 mg/day or 120 mg/kg/day, whichever is less.

• Long-term, high-dose aspirin therapy puts children at increased risk for Reye's syndrome.





This action plan is your "checklist" to make sure you and your child are prepared after your recent hospitalization for Kawasaki Disease. You should complete this form along with your care team before you leave the hospital.

- I received patient information packet on Kawasaki disease
 - No anomaly/aneurysm
 - Possible coronary anomaly/aneurysm
- Our first Cardiology Clinic visit will be in 2-3 weeks:

Date of visit:	 	

Provider: _____

Phone number for office contact: ______

• Our first Infectious Disease Clinic visit is in 2-3 weeks:

Date of visit: _____

Provider: _____

Phone number for office contact: _____

- At my child's first visits, the Cardiology and Infectious Disease Teams will arrange for future follow-up visits.
- I understand my child is to continue aspirin until instructed to stop by the cardiologist seen outside the hospital (Aspirin usually continues for 6-8 weeks).

I understand the following symptoms should make me worry. If any of the following are present, I will contact the Infectious Disease Doctors at 512-628-1820:

- Fever over 100.4°F
- Conjunctivitis (redness of the eyes)
- Red lips and mouth
- Rash
- Unusual irritability
- Swelling of hands or feet
- Vomiting
- I understand live virus vaccines like the measles vaccine or the chicken pox vaccine should not be given to my child for 11 months after treatment with IVIG for Kawasaki Disease
- I understand that children on aspirin and their families should receive the influenza vaccination.





Kawasaki Disease Principles of Echocardiographic Assessment Evidence Based Outcome Center



-Primary aim

-Identify coronary artery involvement, pericarditis, and/or myocarditis

-Timing of echocardiography

-Uncomplicated Kawasaki

- -At time of diagnosis
 - -Two-three weeks

-Six to eight weeks

-Complicated Kawasaki

-At minimum, should adhere to echocardiography timing for uncomplicated Kawasaki

-Increased frequency of imaging may be necessary and should be determined by clinical provider

-Optimization of overall image assessment (improving quality and resolution)

-Plan for possible sedation in children between 12mo-3yrs

-Use highest possible frequency transducer

-Use cine loops/still frame images in conjunction with color Doppler imaging

-Reduce two-dimensional gain and compression

-Use low Nyquist limit to optimize visualization of normal diastolic coronary flow

-Echocardiographic report content

-Coronary arteries

-Visualization and location of coronary arteries

-Presence and description of coronary abnormalities

-Summary comment in conclusions about presence/absence of coronary involvement

-Valvular function

-Biventricular systolic function

-Presence of pericardial effusion

-Presence of pleural effusions

-Coronary artery assessment

-Should be performed in multiple imaging planes

-Optimal views to attain imaging of each coronary should be attempted

-Method of measurement

- inner edge to inner edge of the vessel wall and not measured at the level of normal branching -Descriptions of coronaries should use specific descriptive terms

-Additional resources

-Normal coronary artery diameters with mean and standard deviation

-Additional information about Kawasaki

-Atypical Kawasaki-Echocardiographic Assessment

-KD Coronary Echo Nomenclature








Optimal Views to Image Coronary Arteries

-Left main coronary artery (LMCA): -parasternal short axis at level of aortic valve -parasternal long axis toward PA -subcostal left ventricular long axis -Left anterior descending (LAD): -parasternal short axis at level of aortic valve -parasternal long axis toward PA -parasternal short axis of left ventricle -Left circumflex (LCx): -parasternal short axis at level of aortic valve -apical 4-chamber in MV AV groove -Right coronary artery (RCA): -proximal segment: -parasternal short axis at level of aortic valve -parasternal long axis toward the TV -subcostal coronal projection of RVOT -subcostal short axis at level of AV groove -middle segment: -parasternal long axis of left ventricle toward TV -apical 4-chamber -subcostal left ventricular long axis -subcostal short axis at level of AV groove -distal segment -apical 4-chamber (inferior) -subcostal atrial long axis (inferior) -Posterior descending artery (PDA): -apical 4-chamber (inferior) -subcostal atrial long axis (inferior) -parasternal long axis (inferior tangential) imaging







Kawasaki Disease Principles of Echocardiographic Assessment Evidence Based Outcome Center



Method of Measurement (inner-to-inner)

-Left main coronary artery (LMCA)

- Measure in the mid-position, distal to the flaring often seen near the aortic orifice and before the first bifurcation

-Left anterior descending (LAD)

- Measure distal to the bifurcation and before the first marginal branch

-Right coronary artery (RCA)

- Measure in the relatively straight section of artery just after the initial rightward turn from the anterior facing sinus of Valsalva



-Specific terminology should be used to describe coronary abnormalities seen in patients with Kawasaki disease in order to improve interoperator reliability between reports

-Main features of coronary artery involvement:

-Dilatation (intra-luminal diameter Z-score of \geq 2.5mm)

-Ectatic:

-Uniform: dilated long segment


-Segmented: multiple dilatations joined by normal or stenotic areas

-Lack of tapering of the distal coronary vessel


-Perivascular brightness

-Aneurysm formation

-Fusiform: spindle-shaped, gradual tapering from normal to dilated segment -Saccular: spherical, acute transition from normal to dilated segment



dell children's Ascension Last Updated: January 2024





DELL CHILDREN'S MEDICAL CENTER EVIDENCE-BASED OUTCOMES CENTER





KD Coronary Echo Nomenclature


	Associated Nomenclature	Description	Clinical Relevance
	Normal, No aneurysm or ectasia, Unremarkable	Z score less than +2.5, qualitatively regular lumen and wall appearance	
	Echo-bright, Prominent	Z score normal, no significant wall contour irregularity, qualitative appearance is bright or mildly dilated	No clinical significance but meant to call attention to target area on subsequent interrogation
	Somewhat irregular, mildly dilated, mild ectasia	Z score normal or borderline, irregular contour of walls, +/- echobright,	Limited clinical significance, may indicate potential for future aneurysm. Does not dictate need for therapeutic intervention
	Saccular aneurysm	Z score of dilated area > +2.5. Surrounding area may be normal size	Abnormal
\sim	Ectasia, multiple small aneurysms, dilated	Z scores > +2.5. Diffusely irregular contour to vessel walls	Abnormal
\sim	Fusiform aneurysm	Z scores > +2.5, frequently larger. Aneurysm extends over millimeters and is of varied diameters	





Normal Coronary Diameters

-Mean and prediction limits for 2 and 3 SDs for size of LAD (A), proximal RCA (B), and LMCA (C) according to body surface area for children <18 years old. Adapted from de Zorzi, Newburger, J. W. *et al.* Pediatrics 2004;114:1708-33.





Kawasaki Disease Principles of Echocardiographic Assessment Evidence Based Outcome Center



Additional Information about Kawasaki

-Common sites of coronary involvement (from highest to lowest frequency):

-Proximal LAD -Proximal RCA -LMCA -LCx -Distal RCA -Junction of RCA and PDA

-Risk stratification of aneurysms

-Smaller aneurysms/fusiform aneurysms have greater chance of resolution -Distal coronary artery aneurysms tend to regress more rapidly than proximal aneurysms

-Cardiovascular disease

-History of Kawasaki disease may increase risk for adult cardiovascular disease

-Studies show abnormal vascular endothelial function, intimal thickness and abnormal lipid profiles







EBOC Project Owner: Sarmistha Hauger, MD

Revision History

Date Approved: November 2, 2016

Last Review Date: January 2024 - Literature review post 2016. Updates to Diagnostic Algorithm, definition of Z-scores, expansion of thrombolytic management, high-risk management with steroids.

2016 Kawasaki Disease EBOC Team:

Kenneth Shaffer, MD Sarmistha B. Hauger, MD Gregory Johnson, MD Wade Mincher, MD Winnie Whitaker, MD Andy Kienstra, MD Ruy Carrasco, MD Maira Souza, RN Kathryn Merkel, PharmD Jamie James Randy Bobbitt Erin Spousta, RN Patrick Boswell

2024 Kawasaki Disease EBOC Team:

Sarmistha B. Hauger, MD Lynn Thoreson, DO Janet Orrock, MD Cori Christenholz, PA Jenna Summerlin, PharmD Kenneth Shaffer, MD Alan Mincher, MD Karen Hasbani, MD Lynsey Vaughan, MD Rachel Downey, MSN, APRN Arun Gurunathan, MD Carmen Garudo, EBOC PM

EBOC Committee:

Sarmistha B. Hauger, MD Terry Stanley, DNP, RN, NE-BC Mark Shen, MD Deb Brown, RN Robert Schlechter, MD Levy Moise, MD Sujit Iyer, MD Tory Meyer, MD Nilda Garcia, MD Meena Iyer, MD Michael Auth, DO

2024 EBOC Leadership Team:

Sarmistha B. Hauger, MD Lynn Thoreson, DO Lynsey Vaughan, MD Tory Meyer, MD Meena Iyer, MD Patty Click, RN Amanda Puro, MD Sheryl Yanger, MD Nilda Garcia, MD

